For how we live.
An observational study of 8,127 UK women on GLP-1 drugs, almost all tirzepatide, reported 16.1 kg average loss at six months and 91.4% retention. There was no control arm.
In a 462-person phase 3 trial, a synthesised copy of semaglutide, HD1916, cut body weight 13.1% over 44 weeks against 14.4% for the branded drug — inside the margin set for calling them equivalent.
In the phase 3 SYNCHRONIZE-2 trial, the glucagon/GLP-1 dual agonist beat placebo on weight over 76 weeks. The effect was solid but smaller than the class leaders manage, and the maker funded it.
ZUPREME 1 tested a once-weekly amylin analogue that works differently from GLP-1 drugs, finding up to 9.4% weight loss at 28 weeks and gastrointestinal side-effects close to placebo. Zealand Pharma funded it.
In TRIUMPH-1, a triple hormone-receptor agonist produced a 25% average weight loss at the top dose over 80 weeks, and also eased knee pain and sleep apnoea. The trial was funded by Eli Lilly.
In the LOSE-AF trial, an eight-month low-calorie programme cut weight by 9.7% in older adults with AF. It did not change their symptoms, their AF burden, or their need for further rhythm treatment.
Visceral fat packed around the organs tends to be shed preferentially with modest weight loss. What lingers is subcutaneous fat — and you cannot choose where it comes off, which is what makes the belly feel stubborn.
No. Sweat is how the body sheds heat, not fat. The weight lost in a hot workout or a sauna is water, and it comes back the moment you rehydrate.
You cannot burn fat off a specific area by exercising it. When researchers trained a single limb or drilled abdominal muscles for weeks, fat came off the body generally, not the spot being worked.
Short sleep is tied to obesity, and experiments suggest the link is partly causal. Adults told to sleep longer ate about 270 fewer calories a day; dieters who slept less lost far less of their weight as fat.
Barely, and some carry real risk. Caffeine has a small, measurable effect; the other headline 'thermogenic' ingredients mostly don't, and high-dose green tea extract has caused liver injury.
Losing weight lowers resting metabolism and keeps it low — Biggest Loser contestants ran hundreds of calories below baseline six years on. But that brake slows loss; it does not store fat.
The advice to lose weight slowly assumes fast loss is regained faster. Two randomised trials found the rate barely affects long-term regain — though rapid loss can cost more lean mass and carries its own risks.
Exercising before breakfast shifts which fuel your body uses during the session, but pooled trials find no meaningful edge for weight or body-fat loss over the same workout done fed.
Across 23 cohort studies and 441,199 people, large weight fluctuation was linked to a 41% higher risk of death. Whether the cycling itself does harm, or reflects who cycles, the data cannot fully separate.
A six-month randomised trial found liver-fat improvement tracked weight loss and lower ultra-processed food intake, not whether people were assigned a Mediterranean or low-carbohydrate pattern.
Chronic stress is linked to weight gain, and cortisol is one plausible route. But the measured associations are modest, and cortisol is a contributor, not the master switch that supplement marketing implies.
Told to cut fat or cut carbs, dieters in a 609-person Stanford trial lost 5.3 versus 6.0 kg over a year — a 0.7 kg gap. An 811-person trial agreed: the calorie deficit, not the macronutrient ratio, drives weight loss.
Randomised trials show a Palaeolithic diet trims weight and risk markers in the short term. A two-year trial found the early edge over an ordinary healthy diet had mostly faded — and that people struggled to stick to it.
A critical review went looking for clinical proof that commercial detox diets remove toxins or keep weight off. It found almost none, and no randomised trial of a commercial detox diet in humans at all.
A 2025 meta-analysis of 10 trials found small, short-term reductions in weight and BMI — but the studies were heterogeneous, and the viral single trial that fuelled the hype is one small study, not a settled result.
The first randomised head-to-head trial of the two obesity drugs gave 751 adults the maximum tolerated dose of each for 72 weeks. Tirzepatide cut weight by 20.2%, semaglutide by 13.7%.
The line is marketing, not trial data. A meta-analysis of 13 randomised trials found adding breakfast raised daily calories and, if anything, nudged weight up, not down. A controlled feeding trial explains why.
Six years after 'The Biggest Loser', contestants had regained most of the weight — and their resting metabolism was still running 500 calories a day slower than expected. The diet triggers a defence that outlasts it.
An unplanned cheat day can erase a week's calorie deficit and has no trial support. Structured diet breaks are different — one trial found they improved weight loss, though another found no body-composition edge.
Prediabetes is a high-risk state, not a diagnosis of diabetes. In the trial that defined the field, lifestyle change cut progression by 58 percent — and returning to normal glucose carried a benefit of its own.
Amycretin, a single molecule that activates both the GLP-1 and amylin receptors, produced up to 24.3% weight loss over 36 weeks in a 125-person study. The primary goal, though, was safety — not weight.
In a company-funded randomised trial, adults who lost weight then took pasteurised Akkermansia muciniphila regained 1.2 kg over 24 weeks versus 3.2 kg on placebo — a modest effect in 90 people.
A meta-analysis of 11 trials put the change in a healthy man's resting testosterone from training at zero. Endurance work can lower it; losing body fat is the lever that reliably raises it.
A new analysis of the REDEFINE 1 trial reframes obesity treatment around reaching a normal BMI and waist size, not just percentage lost. The combination beat semaglutide alone on that measure.
Two randomised trials found a 500 ml glass of water before meals adds a modest extra loss — about 1.3 kg over 12 weeks in one. The effect is real but small, short-term, and no substitute for the diet itself.
A kilogram of muscle burns about 13 calories a day at rest — far less than the fitness-marketing figure implies. But resistance training does nudge resting metabolism up, by roughly 96 calories a day in a meta-analysis.
A large study of energy use across the lifespan found it holds steady from age 20 to 60, once body size is accounted for. The midlife metabolic slump is mostly a myth; the decline comes later.
Head-to-head randomised trials find low-carbohydrate and low-fat diets produce similar weight loss over a year or two. The differences that survive are in blood lipids and glycemic control, not the scale.
Substantial, sustained weight loss can return blood sugar to the normal range without drugs in some people diagnosed recently. It is real, it is not a cure, and it fades as the weight comes back.
MariTide antagonises the GIP receptor that tirzepatide switches on, yet in 592 adults it drove 12–16% weight loss over a year — and it is dosed once a month, not once a week.
A transcriptomic sub-study of the CALERIE calorie-restriction trial links 151 genes to preserved leg strength during weight loss, independent of how much body mass was lost.
The glucagon and GLP-1 dual agonist, already approved in China, cut bodyweight 18.1% at 16 mg and 15.6% at 10 mg over 32 weeks versus 0.9% on placebo in a US phase 2 trial.
A meta-analysis of 116 randomised trials found weight, waist and body fat falling steadily up to 300 minutes a week. In one 24-week trial, 48% of participants compensated by about 308 kcal a day.
Heavy drinking tracks with weight gain fairly consistently. For light-to-moderate drinking, the evidence is genuinely mixed — and confounded by who drinks that way.
GLORY-2 randomised 461 Chinese adults with obesity to a weekly GLP-1/glucagon dual agonist or placebo; weight fell 16.65% versus 1.50% at 60 weeks, alongside high rates of nausea and vomiting.
MASLD is excess fat in the liver unrelated to alcohol, and about 30% of adults have it. The best-evidenced way to reverse the inflamed form is weight loss — and how much you lose tracks how much the liver recovers.
In moderate-to-heavy drinkers who stopped for a month, insulin resistance fell by a quarter and two cancer-related growth factors dropped sharply — changes a matched control group did not show.
Petrelintide, a long-acting amylin analogue given without a GLP-1 drug, reduced bodyweight by up to 8.6% at 16 weeks across two small phase 1 trials and was well tolerated. The finding is early.
Pooled across 23 trials, weight-loss apps beat a waitlist by about 2 kg at six months. Which features the app had made no measurable difference; adherence, which falls over time, is the real variable.
In TRANSCEND-T2D-1, the triple-hormone agonist cut HbA1c up to 1.12 points beyond placebo over 40 weeks and trimmed bodyweight 15.3% at the top dose in early type 2 diabetes.
The trial's own primary outcome — inflammation — was flat. What the new analysis adds is a molecular account of why the fat loss did not translate into the benefits fasting is sold on.
A Spanish trial in 4,746 adults compared an energy-reduced Mediterranean diet plus exercise against the same diet eaten freely. Over six years the absolute gap was 12.0% versus 9.5%.
Fifty-five English adults ate two eight-week diets that both followed the UK Eatwell Guide. Both produced weight loss. The minimally processed version produced about one percentage point more.
A BMJ network meta-analysis of 6,582 adults finds alternate day fasting the only intermittent method that beat continuous calorie restriction — by 1.29 kg, mostly in short trials.